{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T15:32:26Z","timestamp":1790695946759,"version":"4.1.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2019,6,10]],"date-time":"2019-06-10T00:00:00Z","timestamp":1560124800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,6,10]],"date-time":"2019-06-10T00:00:00Z","timestamp":1560124800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2019,9]]},"DOI":"10.1007\/s12185-019-02685-z","type":"journal-article","created":{"date-parts":[[2019,6,10]],"date-time":"2019-06-10T08:02:54Z","timestamp":1560153774000},"page":"322-330","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["VS38 as a promising CD38 substitute antibody for flow cytometric detection of plasma cells in the daratumumab era"],"prefix":"10.1007","volume":"110","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2688-8522","authenticated-orcid":false,"given":"Shumpei","family":"Mizuta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahito","family":"Kawata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Kawabata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noriko","family":"Yamane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saya","family":"Mononobe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takao","family":"Komai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuke","family":"Koba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoya","family":"Ukyo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akira","family":"Tamekane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsumasa","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,6,10]]},"reference":[{"key":"2685_CR1","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1056\/NEJMra1011442","volume":"364","author":"A Palumbo","year":"2011","unstructured":"Palumbo A, Anderson K. Multiple myeloma. N Engl J Med. 2011;364:1046\u201360.","journal-title":"N Engl J Med."},{"key":"2685_CR2","doi-asserted-by":"publisher","first-page":"4017","DOI":"10.1182\/blood-2008-05-159624","volume":"112","author":"B Paiva","year":"2008","unstructured":"Paiva B, Vidriales MB, Cerver\u00f3 J, Mateo G, P\u00e9rez JJ, Montalb\u00e1n MA, et al. Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation. Blood. 2008;112:4017\u201323.","journal-title":"Blood"},{"key":"2685_CR3","doi-asserted-by":"publisher","first-page":"2540","DOI":"10.1200\/JCO.2012.46.2119","volume":"31","author":"AC Rawstron","year":"2013","unstructured":"Rawstron AC, Child JA, de Tute RM, Davies FE, Gregory WM, Bell SE, et al. Minimal residual disease assessed by multiparameter flow cytometry in multiple myeloma: impact on outcome in the Medical Research Council Myeloma IX Study. J Clin Oncol. 2013;31:2540\u20137.","journal-title":"J Clin Oncol."},{"key":"2685_CR4","doi-asserted-by":"publisher","first-page":"2094","DOI":"10.1038\/leu.2017.29","volume":"31","author":"J Flores-Montero","year":"2017","unstructured":"Flores-Montero J, Sanoja-Flores L, Paiva B, Puig N, Garc\u00eda-S\u00e1nchez O, B\u00f6ttcher S, et al. Next Generation Flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma. Leukemia. 2017;31:2094\u2013103.","journal-title":"Leukemia"},{"key":"2685_CR5","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.1182\/blood-2014-11-568907","volume":"125","author":"B Paiva","year":"2015","unstructured":"Paiva B, van Dongen JJ, Orfao A. New criteria for response assessment: role of minimal residual disease in multiple myeloma. Blood. 2015;125:3059\u201368.","journal-title":"Blood"},{"key":"2685_CR6","doi-asserted-by":"publisher","first-page":"2503","DOI":"10.1093\/annonc\/mdx340","volume":"28","author":"H Takamatsu","year":"2017","unstructured":"Takamatsu H, Takezako N, Zheng J, Moorhead M, Carlton VEH, Kong KA, et al. Prognostic value of sequencing-based minimal residual disease detection in patients with multiple myeloma who underwent autologous stem-cell transplantation. Ann Oncol. 2017;28:2503\u201310.","journal-title":"Ann Oncol."},{"key":"2685_CR7","doi-asserted-by":"publisher","first-page":"2456","DOI":"10.1182\/blood-2018-06-858613","volume":"132","author":"A Perrot","year":"2018","unstructured":"Perrot A, Lauwers-Cances V, Corre J, Robillard N, Hulin C, Chretien ML, et al. Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma. Blood. 2018;132:2456\u201364.","journal-title":"Blood."},{"key":"2685_CR8","doi-asserted-by":"publisher","first-page":"1908","DOI":"10.1038\/leu.2012.120","volume":"26","author":"JJ van Dongen","year":"2012","unstructured":"van Dongen JJ, Lhermitte L, B\u00f6ttcher S, Almeida J, van der Velden VH, Flores-Montero J, et al. EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes. Leukemia. 2012;26:1908\u201375.","journal-title":"Leukemia"},{"key":"2685_CR9","doi-asserted-by":"publisher","first-page":"284","DOI":"10.3324\/haematol.2010.030759","volume":"96","author":"MS van der Veer","year":"2011","unstructured":"van der Veer MS, de Weers M, van Kessel B, Bakker JM, Wittebol S, Parren PW, et al. Towards effective immunotherapy of myeloma: enhanced elimination of myeloma cells by combination of lenalidomide with the human CD38 monoclonal antibody daratumumab. Haematologica. 2011;96:284\u201390.","journal-title":"Haematologica"},{"key":"2685_CR10","doi-asserted-by":"publisher","first-page":"e368","DOI":"10.3324\/haematol.2017.169235","volume":"102","author":"A Oberle","year":"2017","unstructured":"Oberle A, Brandt A, Alawi M, Langebrake C, Janjetovic S, Wolschke C, et al. Long-term CD38 saturation by daratumumab interferes with diagnostic myeloma cell detection. Haematologica. 2017;102:e368\u2013e370370.","journal-title":"Haematologica"},{"key":"2685_CR11","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1136\/jcp.47.5.418","volume":"47","author":"H Turley","year":"1994","unstructured":"Turley H, Jones M, Erber W, Mayne K, de Waele M, Gatter K. VS38: a new monoclonal antibody for detecting plasma cell differentiation in routine sections. J Clin Pathol. 1994;47:418\u201322.","journal-title":"J Clin Pathol."},{"key":"2685_CR12","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1136\/jcp.49.3.205","volume":"49","author":"JH Shanks","year":"1996","unstructured":"Shanks JH, Banerjee SS. VS38 immunostaining in melanocytic lesions. J Clin Pathol. 1996;49:205\u20137.","journal-title":"J Clin Pathol."},{"key":"2685_CR13","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1016\/S0344-0338(97)80038-6","volume":"193","author":"I Sulzbacher","year":"1997","unstructured":"Sulzbacher I, Fuchs M, Chott A, Lang S. Expression of VS38 in osteoblasts and stroma cells of bone tumors. Pathol Res Pract. 1997;193:613\u20136.","journal-title":"Pathol Res Pract."},{"key":"2685_CR14","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1046\/j.1365-2559.1997.d01-599.x","volume":"30","author":"SS Banerjee","year":"1997","unstructured":"Banerjee SS, Shanks JH, Hasleton PS. VS38 immunostaining in neuroendocrine tumours. Histopathology. 1997;30:256\u20139.","journal-title":"Histopathology"},{"key":"2685_CR15","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1136\/jcp.50.6.485","volume":"50","author":"AH Banham","year":"1997","unstructured":"Banham AH, Turley H, Pulford K, Gatter K, Mason DY. The plasma cell associated antigen detectable by antibody VS38 is the p63 rough endoplasmic reticulum protein. J Clin Pathol. 1997;50:485\u20139.","journal-title":"J Clin Pathol."},{"key":"2685_CR16","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s13569-017-0083-5","volume":"7","author":"ES Hookway","year":"2017","unstructured":"Hookway ES, Orosz Z, Uchihara Y, Grigoriadis A, Hassan AB, Oppermann U, et al. Utility of VS38c in the diagnostic and prognostic assessment of osteosarcoma and other bone tumours\/tumour-like lesions. Clin Sarcoma Res. 2017;7:17.","journal-title":"Clin Sarcoma Res."},{"key":"2685_CR17","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1002\/cyto.b.21228","volume":"90","author":"M Arroz","year":"2016","unstructured":"Arroz M, Came N, Lin P, Chen W, Yuan C, Lagoo A, et al. Consensus guidelines on plasma cell myeloma minimal residual disease analysis and reporting. Cytometry B Clin Cytom. 2016;90:31\u20139.","journal-title":"Cytometry B Clin Cytom."},{"key":"2685_CR18","doi-asserted-by":"publisher","first-page":"2671","DOI":"10.1002\/j.1460-2075.1984.tb02192.x","volume":"3","author":"A Hasilik","year":"1984","unstructured":"Hasilik A, Pohlmann R, Olsen RL, von Figura K. Myeloperoxidase is synthesized as larger phosphorylated precursor. EMBO J. 1984;3:2671\u20136.","journal-title":"EMBO J."},{"key":"2685_CR19","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1002\/cyto.b.21269","volume":"90","author":"F Pojero","year":"2016","unstructured":"Pojero F, Flores-Montero J, Sanoja L, P\u00e9rez JJ, Puig N, Paiva B, et al. EuroFlow group. Utility of CD54, CD229, and CD319 for the identification of plasma cells in patients with clonal plasma cell diseases. Cytometry B Clin Cytom. 2016; 90:91-100.","journal-title":"Cytometry B Clin Cytom"},{"key":"2685_CR20","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.critrevonc.2013.04.003","volume":"88","author":"A Veillette","year":"2013","unstructured":"Veillette A, Guo H. CS1, a SLAM family receptor involved in immune regulation, is a therapeutic target in multiple myeloma. Crit Rev Oncol Hematol. 2013;88:168\u201377.","journal-title":"Crit Rev Oncol Hematol."},{"key":"2685_CR21","first-page":"599","volume":"13","author":"P Sondergeld","year":"2015","unstructured":"Sondergeld P, van de Donk NW, Richardson PG, Plesner T. Monoclonal antibodies in myeloma. Clin Adv Hematol Oncol. 2015;13:599\u2013609.","journal-title":"Clin Adv Hematol Oncol."},{"key":"2685_CR22","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1182\/blood-2016-03-703439","volume":"128","author":"IS Nijhof","year":"2016","unstructured":"Nijhof IS, Casneuf T, van Velzen J, van Kessel B, Axel AE, Syed K, et al. CD38 expression and complement inhibitors affect response and resistance to daratumumab therapy in myeloma. Blood. 2016;128:959\u201370.","journal-title":"Blood"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-019-02685-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12185-019-02685-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-019-02685-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,8]],"date-time":"2020-06-08T23:43:28Z","timestamp":1591659808000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12185-019-02685-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6,10]]},"references-count":22,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,9]]}},"alternative-id":["2685"],"URL":"https:\/\/doi.org\/10.1007\/s12185-019-02685-z","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,6,10]]},"assertion":[{"value":"6 January 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 May 2019","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 May 2019","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 June 2019","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}